GWAS And Candidate SNPs For COPD And Lung Cancer Combine To Identify Lung Cancer Susceptibility: Validation In A Prospective Study

Young, Robert P.; Hay, Bryan A.; Gamble, Greg

doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3738

Cited by 5 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A research team in New Zealand has shown a correlation between a genetic test, consisting of 19 single nucleotide polymorphisms (SNPs) and one deletion mutation, and cancer risk (Additional file 1 : Appendix S1). When a risk score was calculated from the results of the genetic test and clinical risk factors (COPD, family history of lung cancer and age), this was an accurate predictor for the development of lung cancers [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial

Nichols

Grob

Kite³

et al. 2017

BMC Res Notes

View full text Add to dashboard Cite

BackgroundAs genetic tests become cheaper, the possibility of their widespread availability must be considered. This study involves a risk score for lung cancer in smokers that is roughly 50% genetic (50% clinical criteria). The risk score has been shown to be effective as a smoking cessation motivator in hospital recruited subjects (not actively seeking cessation services).MethodsThis was an RCT set in a United Kingdom National Health Service (NHS) smoking cessation clinic. Smokers were identified from medical records. Subjects that wanted to participate were randomised to a test group that was administered a gene-based risk test and given a lung cancer risk score, or a control group where no risk score was performed. Each group had 8 weeks of weekly smoking cessation sessions involving group therapy and advice on smoking cessation pharmacotherapy and follow-up at 6 months. The primary endpoint was smoking cessation at 6 months. Secondary outcomes included ranking of the risk score and other motivators.Results67 subjects attended the smoking cessation clinic. The 6 months quit rates were 29.4%, (10/34; 95% CI 14.1–44.7%) for the test group and 42.9% (12/28; 95% CI 24.6–61.2%) for the controls. The difference is not significant. However, the quit rate for test group subjects with a “very high” risk score was 89% (8/9; 95% CI 68.4–100%) which was significant when compared with the control group (p = 0.023) and test group subjects with moderate risk scores had a 9.5% quit rate (2/21; 95% CI 2.7–28.9%) which was significantly lower than for above moderate risk score 61.5% (8/13; 95% CI 35.5–82.3; p = 0.03).ConclusionsOnly the sub-group with the highest risk score showed an increased quit rate. Controls and test group subjects with a moderate risk score were relatively unlikely to have achieved and maintained non-smoker status at 6 months. ClinicalTrials.gov ID NCT01176383 (date of registration: 3 August 2010)Electronic supplementary materialThe online version of this article (doi:10.1186/s13104-017-2831-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial

Nichols

Grob

Kite³

et al. 2017

BMC Res Notes

View full text Add to dashboard Cite

show abstract

“…With the progress of research, passive smoking and exposure to cooking fumes have attracted more and more attention [19,20]. Additionally, there has been a longstanding interest in genetic susceptibility to lung cancer, and recent studies have established its definite role [6,21]. However, how to make a comprehensive evaluation about risks of lung cancer still remains a significant, but a little bit confusing, problem.…”

Section: Discussionmentioning

confidence: 99%

Early Lung Cancer Detection Using the Self-Evaluation Scoring Questionnaire and Chest Digital Radiography: A 3-Year Follow-up Study in China

et al. 2012

View full text Add to dashboard Cite

The standard definition of high-risk individuals for lung cancer was not uniform and the value of chest digital radiography (DR) in lung cancer screening was still unproven. The aim of this study was to assess whether the original questionnaire named as "Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer" combined with DR examinations could detect early stage of lung cancer effectively. The Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer had been designed in previous studies. Subjects with scores over 116 points were regarded as high-risk individuals and underwent the current DR scans at least once a year from 2007 to 2009. Noncalcified nodules with a diameter over 30 mm, along with enlarged pulmonary hilus and atelectasis, were considered to be positive and subjected to further special examinations. Efficacy of the scoring questionnaire combined with DR scans was estimated by 3-year results. Among 1,537 subjects, 13, 11, and 7 were diagnosed with lung cancer in the first, second, J Digit Imaging (2013) 26:72-81 DOI 10.1007 and third year, respectively, indicating the detection rate of 2.02 % (31/1,537). In addition, 77.42 % (24/31) of the patients were in stage I and 51.61 % (16/31) were adenocarcinomas. For the 31 cases, 28 were defined as detected cancers, while the other three were interval ones, only accounting for 0.20 % (3/1,504) of individuals with negative judgments. The protocol of Self-evaluation Scoring Questionnaire for High-risk Individuals of Lung Cancer combined with DR scans is a cost-effective and safe approach to detect early stage of lung cancer.

show abstract

“…Patients who reply stating that they wish to stop smoking will be randomised (stratified randomisation to ensure equivalent age and gender mix) to two clinics (Figure 3 ) only one of which will include the gene-based test. Previous trials of genetic testing in association with smoking cessation achieved 83-100% of participants opting for the test depending on the method of recruitment [ 8 , 21 ]. There will be two mailings with SAEs for recruitment with the aim of recruiting at least 30 subjects per clinic (see Power calculations under heading “statistics”).…”

Section: Method/designmentioning

confidence: 99%

“…However, over 80% of smokers would like to know their personal risk of lung cancer [ 4 ]. There is a plausible three way link between biomarkers for chronic obstructive pulmonary disease (COPD), a set of 20 single nucleotide polymorphisms (SNPs) associated with cancer risk and lung cancer [ 5 - 8 ] (Figure 1 ). Research has shown a strong association between a high lung cancer susceptibility score derived from family history of cancer, the 20 SNPs, COPD history (Auckland formula) and the development of lung cancers whereas healthy smokers matched for age, gender and lifetime smoking habits had a relatively low score (n = 446 lung cancer subjects, 484 healthy current smokers).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk

et al. 2014

View full text Add to dashboard Cite

BackgroundA gene-based estimate of lung cancer risk in smokers has been shown to act as a smoking cessation motivator in hospital recruited subjects. The objective of this trial is to determine if this motivator is as effective in subjects recruited from an NHS primary care unit.Method/DesignSubjects will be recruited by mailings using smoking entries on the GP electronic data-base (total practice population = 32,048) to identify smokers who may want to quit. Smoking cessation clinics based on medical centre premises will run for eight weeks. Clinics will be randomised to have the gene-based test for estimation of lung cancer risk or to act as controls groups. The primary endpoint will be smoking cessation at eight weeks and six months. Secondary outcomes will include ranking of the gene-based test with other smoking cessation motivators.DiscussionThe results will inform as to whether the gene-based test is both effective as motivator and acceptable to subjects recruited from primary care.Trial registrationRegistered with Clinical Trials.gov, Registration number: NCT01176383.

show abstract

GWAS And Candidate SNPs For COPD And Lung Cancer Combine To Identify Lung Cancer Susceptibility: Validation In A Prospective Study

Cited by 5 publications

References 0 publications

Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial

Using a genetic/clinical risk score to stop smoking (GeTSS): randomised controlled trial

Early Lung Cancer Detection Using the Self-Evaluation Scoring Questionnaire and Chest Digital Radiography: A 3-Year Follow-up Study in China

Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk

Contact Info

Product

Resources

About